Advertisement

Thioridazine and arrhythmia

NEW YORK, August 3 (Praxis Press) The antipsychotic drug, Mellaril (thioridazine) has been shown to prolong patients' QTc interval, which can lead to a type of ventricular tachycardia known as torsades de pointes and potentially sudden death. At the request of the US Food and Drug administration (FDA), the manufacturer of the drug, Novartis, has now added a black box warning on the drug's label in order to alert physicians to its tendency of prolonging a patient's heartbeat interval. Now Mellari

August 8, 2000

NEW YORK, August 3 (Praxis Press) The antipsychotic drug, Mellaril (thioridazine) has been shown to prolong patients' QTc interval, which can lead to a type of ventricular tachycardia known as torsades de pointes and potentially sudden death. At the request of the US Food and Drug administration (FDA), the manufacturer of the drug, Novartis, has now added a black box warning on the drug's label in order to alert physicians to its tendency of prolonging a patient's heartbeat interval. Now Mellaril is indicated only for patients with schizophrenia who either cannot tolerate other antipsychotic drugs or who fail to respond to them.

Advertisement
The Scientist
The Scientist

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
NuAire
NuAire
Advertisement
The Scientist
The Scientist